- Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
- Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
- Lyell Immunopharma Announces Participation in March Investor Conferences
- Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
More ▼
Key statistics
As of last trade, Lyell Immunopharma Inc (LYEL:NSQ) traded at 1.68, 41.95% above the 52 week low of 1.18 set on Jun 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.60 |
---|---|
High | 1.70 |
Low | 1.58 |
Bid | 1.67 |
Offer | 1.68 |
Previous close | 1.63 |
Average volume | 698.92k |
---|---|
Shares outstanding | 254.94m |
Free float | 207.35m |
P/E (TTM) | -- |
Market cap | 415.55m USD |
EPS (TTM) | -0.9057 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 20:32 BST.
More ▼